Advance Therapy Revenue and Competitors
Claim your profile
Estimated Revenue & Valuation
- Advance Therapy's estimated annual revenue is currently $13.1M per year.
- Advance Therapy's estimated revenue per employee is $243,000
Employee Data
- Advance Therapy has 54 Employees.
- Advance Therapy grew their employee count by -7% last year.
Advance Therapy Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $305.4M | 808 | 6% | N/A | N/A |
#2 | $5.1M | 27 | -13% | N/A | N/A |
#3 | $24.3M | 90 | -25% | N/A | N/A |
#4 | $60.3M | 203 | 17% | N/A | N/A |
#5 | $28.6M | 106 | 9% | N/A | N/A |
#6 | $30M | 111 | -8% | N/A | N/A |
#7 | $84.1M | 283 | -3% | N/A | N/A |
#8 | $107.7M | 319 | 23% | N/A | N/A |
#9 | $13.4M | 55 | 4% | N/A | N/A |
#10 | $561.4M | 1454 | 40% | $1.1B | N/A |
What Is Advance Therapy?
N/A
Total Funding
54
Number of Employees
$13.1M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Advance Therapy News
2022-04-20 - Coeptis Combines with Bull Horn in SPAC Deal to Advance ...
CD38-GEAR-NK is a natural killer (NK) cell- based therapy candidate that supports combination treatment with anti-CD38 monoclonal antibodies (...
2022-04-19 - Novel CAR T Therapy for Solid Tumors: 'Exciting Advance'
Now, a new CAR T construct that targets the tumor-specific antigen claudin 6 (CLDN6) is showing promising preliminary activity against relapsed...
2022-04-13 - Cell therapy biotech raises $120M to advance therapy to treat common cornea
condition
Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that affects millions of people.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.8M | 54 | 17% | N/A |
#2 | $11.5M | 54 | -5% | $80M |
#3 | $13.1M | 54 | -2% | N/A |
#4 | $6.8M | 54 | 2% | N/A |
#5 | $5.5M | 54 | 8% | N/A |